| Literature DB >> 27381510 |
Alix Pierron1,2,3, Sabria Mimoun1,2, Leticia S Murate1,4, Nicolas Loiseau1,2, Yannick Lippi1,2, Ana-Paula F L Bracarense4, Gerd Schatzmayr3, Jian Wei He5, Ting Zhou5, Wulf-Dieter Moll3, Isabelle P Oswald1,2.
Abstract
Bacteria are able to de-epoxidize or epimerize deoxynivalenol (DON), a mycotoxin, to deepoxy-deoxynivalenol (deepoxy-DON or DOM-1) or 3-epi-deoxynivalenol (3-epi-DON), respectively. Using different approaches, the intestinal toxicity of 3 molecules was compared and the molecular basis for the reduced toxicity investigated. In human intestinal epithelial cells, deepoxy-DON and 3-epi-DON were not cytotoxic, did not change the oxygen consumption or impair the barrier function. In intestinal explants, exposure for 4 hours to 10 μM DON induced intestinal lesions not seen in explants treated with deepoxy-DON and 3-epi-DON. A pan-genomic transcriptomic analysis was performed on intestinal explants. 747 probes, representing 323 genes, were differentially expressed, between DON-treated and control explants. By contrast, no differentially expressed genes were observed between control, deepoxy-DON and 3-epi-DON treated explants. Both DON and its biotransformation products were able to fit into the pockets of the A-site of the ribosome peptidyl transferase center. DON forms three hydrogen bonds with the A site and activates MAPKinases (mitogen-activated protein kinases). By contrast deepoxy-DON and 3-epi-DON only form two hydrogen bonds and do not activate MAPKinases. Our data demonstrate that bacterial de-epoxidation or epimerization of DON altered their interaction with the ribosome, leading to an absence of MAPKinase activation and a reduced toxicity.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27381510 PMCID: PMC4933977 DOI: 10.1038/srep29105
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Effects of deepoxy-DON or 3-epi-DON on human intestinal epithelial cells.
Activation of cytotoxicity (Panel A), TEER (Panel B) and OCR (Panel C). (Panel A): Proliferative Caco-2 cells were incubated with increasing concentrations of diluent (♦), DON (◾), deepoxy-DON (▴) or 3-epi-DON (●) for 48 hours. Cell viability evaluated by measurement of ATP, is expressed as % of control cells. (Panel B): Caco-2 cells, differentiated on inserts, were treated with 10 μM of diluent (♦), DON (◾), deepoxy-DON (▴) or 3-epi-DON (●) and TEER was measured. (Panel C): After establishment of baseline oxygen consumption rate in proliferated Caco-2 cells seeded to 1.5 × 104 cells/well, diluent (♦), DON (◾), deepoxy-DON (▴) or 3-epi-DON (●), was injected at final concentration of 10 μM as indicated by the arrow. The rate of oxygen consumption was then measured for the indicated time. For visual clarity, statistical indicators were omitted from the graph. The OCR values are shown as the percent of baseline for each group. Results are expressed as mean ± SEM of 3–4 independent experiments, ***p < 0.001.
Figure 2Comparative effects of deepoxy-DON and 3-epi-DON and DON on morphology of intestinal explants.
Jejunal explants from 4 different animals were exposed for 4 hours, to diluent or 10 μM toxins and stained with HE for histological analysis. Normal villi lined with columnar enterocytes were observed on control explants (Panel A) multifocal villi atrophy (arrow) and cell debris (arrowhead), apical necrosis (insert) on DON explants (Panel B) histological aspects similar to control group on deepoxy-DON (Panel C) or 3-epi-DON (Panel D) explants. Bar 100 μm; insert bar 20 μm.
DON but not deepoxy-DON & 3-epi-DON up-regulated mRNA relative expression levels of pro-inflammatory cytokines and chemokines in pig jejunal explants.
| Cytokines | Explant treatments | |||
|---|---|---|---|---|
| Control | DON | Deepoxy-DON | 3-epi-DON | |
| 1.00 ± 0.40a | 17.4 ± 5.1b | 0.7 ± 0.2a | 0.8 ± 0.3a | |
| 1.00 ± 0.30a | 3.9 ± 1.4b | 0.9 ± 0.2a | 0.9 ± 0.2a | |
| 1.00 ± 0.20a | 4.5 ± 1.2b | 1 ± 0.1a | 0.9 ± 0.2a | |
| 1.00 ± 0.31a | 2.3 ± 0.4b | 1.2 ± 0.2a | 0.9 ± 0.2a | |
| 1.00 ± 0.50a | 15.8 ± 5.6b | 0.8 ± 0.1a | 1.3 ± 0.4a | |
| 1.00 ± 0.30a | 7.9 ± 1.3b | 1.3 ± 0.5a | 1.4 ± 0.5a | |
| 1.00 ± 0.30a | 3.5 ± 0.5b | 1.1 ± 0.4a | 1.1 ± 0.3a | |
Notes: results are expressed in arbitrary units relative to control group. Results are mean ± SEM of 6 animals. Means in a row without a common letter differ (Newman-Keuls test, P < 0.05).
Figure 3Gene expression profile of intestinal explants exposed to deepoxy-DON, 3-epi-DON or DON.
Jejunal explants from 4 different animals were exposed for 4 hours, to diluent or 10 μM toxins and gene expression was analyzed with a 60 K microarray. (Panel A): Venn diagram illustrating the overlaps between the probes significantly up- or down-regulated in response to DON, deepoxy-DON (DOM-1) and 3-epi-DON treatment. (Panel B): Principal Component Analysis of differentially expressed probes between DON, deepoxy-DON (DOM-1), 3-epi-DON and control (747 with BH adjusted p-value < 0.05). (Panel C): Heat map representing differentially expressed probes between DON, deepoxy-DON (DOM-1), 3-epi-DON and control explant. Red and green colors indicate values above and below the mean (average Z-score) respectively. Black color indicates values close to the mean.
Top scored differentially expressed genes in DON treated porcine jejunal explants.
| Gene symbol | Gene name | −log (p-value) | Ratio |
|---|---|---|---|
| a. Up-regulated genes | |||
| IL1B | interleukin 1 beta | 4.428 | 1.29E-11 |
| CCL20 | chemokine (C-C motif) ligand 20 | 3.481 | 1.79E-06 |
| IL1A | interleukin 1. alpha | 3.207 | 6.46E-09 |
| CXCL2 | chemokine (C-X-C motif) ligand 2 | 3.129 | 1.87E-04 |
| IL22 | interleukin 22 | 2.955 | 1.13E-07 |
| PRDM1 | PR domain containing 1 with ZNF domain | 2.793 | 4.76E-06 |
| AREG/AREGB | amphiregulin | 2.662 | 1.94E-11 |
| CSF2 | colony stimulating factor 2 (granulocyte-macrophage) | 2.593 | 1.86E-05 |
| IL8 | interleukin 8 | 2.585 | 1.25E-06 |
| FOSL1 | FOS-like antigen 1 | 2.447 | 4.22E-04 |
| IER3 | immediate early response 3 | 2.446 | 1.95E-04 |
| CCR7 | chemokine (C-C motif) receptor 7 | 2.325 | 1.79E-08 |
| CALCB | calcitonin-related polypeptide beta | 2.313 | 9.03E-11 |
| GADD45A | growth arrest and DNA-damage-inducible alpha | 2.270 | 5.61E-08 |
| TNFAIP3 | tumor necrosis factor alpha-induced protein 3 | 2.260 | 1.36E-08 |
| RND1 | Rho family GTPase 1 | 2.255 | 3.24E-06 |
| IER2 | immediate early response 2 | 2.227 | 3.44E-06 |
| CD83 | CD83 molecule | 2.207 | 1.10E-05 |
| PLAUR | plasminogen activator. urokinase receptor | 2.085 | 9.86E-04 |
| BTG2 | BTG family member 2 | 2.073 | 1.25E-06 |
| IFRD1 | interferon-related developmental regulator 1 | 2.025 | 1.14E-08 |
| RGS1 | regulator of G-protein signaling 1 | 2.020 | 3.24E-06 |
| GEM | GTP binding protein overexpressed in skeletal muscle | 2.013 | 4.52E-05 |
| CCL4 | chemokine (C-C motif) ligand 4 | 2.004 | 6.44E-04 |
| STX11 | syntaxin 11 | 1.989 | 4.27E-05 |
| GADD45G | growth arrest and DNA-damage-inducible gamma | 1.881 | 2.26E-06 |
| GADD45B | growth arrest and DNA-damage-inducible beta | 1.873 | 9.01E-04 |
| NEDD9 | neural precursor cell expressed developmentally down-regulated 9 | 1.870 | 1.15E-10 |
| LAMA3 | laminin. alpha 3 | 1.858 | 2.07E-05 |
| CD274 | CD274 molecule | 1.846 | 8.75E-11 |
| IL17A | interleukin 17A | 1.844 | 2.11E-11 |
| b. Down-regulated genes | |||
| cation transport regulator homolog 1 ( | −1.696 | 9.18E-04 | |
| ATP-binding cassette sub-family C (CFTR/MRP) member 2 | −1.015 | 2.45E-06 | |
| solute carrier family 15 (oligopeptide transporter) member 1 | −0.851 | 3.56E-05 | |
| solute carrier family 9 subfamily A (NHE2 cation proton antiporter 2) member 2 | −0.804 | 9.09E-06 | |
| chemokine (C-C motif) ligand 24 | −0.784 | 8.75E-04 | |
| microsomal triglyceride transfer protein | −0.755 | 3.26E-05 | |
| deleted in malignant brain tumors 1 | −0.666 | 2.67E-04 | |
| Malectin | −0.654 | 9.50E-04 | |
| slingshot protein phosphatase 1 | −0.628 | 1.06E-03 | |
| vacuolar protein sorting 26 homolog B ( | −0.610 | 1.04E-03 | |
| angiotensin I converting enzyme 2 | −0.607 | 7.35E-04 | |
| secretoglobin. family 2A member 1 | −0.594 | 2.74E-04 | |
| myeloma overexpressed | −0.592 | 1.58E-04 | |
| natriuretic peptide receptor 3 | −0.582 | 8.74E-04 | |
| Cbl proto-oncogene. E3 ubiquitin protein ligase | −0.574 | 3.70E-04 | |
| procollagen-lysine 2-oxoglutarate 5-dioxygenase 2 | −0.547 | 3.98E-05 | |
| complement component 4 binding protein Alpha | −0.525 | 1.04E-03 | |
| Rho guanine nucleotide exchange factor (GEF) 37 | −0.521 | 9.19E-04 | |
| desumoylating isopeptidase 2 | −0.501 | 3.04E-04 | |
| stomatin (EPB72)-like 3 | −0.487 | 8.33E-04 | |
| unc-119 homolog B ( | −0.467 | 2.42E-04 | |
| zyg-11 related. cell cycle regulator | −0.455 | 4.92E-04 | |
| egl-9 family hypoxia-inducible factor 1 | −0.443 | 2.26E-04 | |
| titin-cap | −0.441 | 8.90E-04 | |
| platelet/endothelial cell adhesion molecule 1 | −0.431 | 1.43E-04 | |
| zinc finger CCHC domain containing 14 | −0.430 | 5.16E-04 | |
| polypeptide N-acetylgalactosaminyltransferase 4 | −0.395 | 6.91E-04 | |
| ankyrin repeat domain 13A | −0.388 | 8.85E-04 | |
| unc-45 homolog A (C. elegans) | −0.377 | 7.64E-04 | |
| tripeptidyl peptidase I | −0.375 | 5.37E-04 | |
| oxysterol binding protein-like 7 | −0.349 | 1.05E-03 | |
Ten top scored canonical pathways differentially regulated in 10 μM DON treated porcine jejuna explants and list of genes in each pathway.
| Ingenuity Canonical Pathways | −log (p-value) | Ratio | Molecules |
|---|---|---|---|
| a. Up-regulated pathways | |||
| 1.18E01 | 1.1E-01 | ||
| 1.13E01 | 1.04E-01 | ||
| 1.11E01 | 7.69E-02 | ||
| 1.07E01 | 3.91E-01 | ||
| 1.01E01 | 1.25E-01 | ||
| 1.01E01 | 4.44E-01 | ||
| 9.55E00 | 1.03E-01 | ||
| 9.48E00 | 1.54E-01 | ||
| 9.41E00 | 1.67E-01 | ||
| 9.4E00 | 1.08E-01 | ||
| b. Down-regulated pathways | |||
| 2.28E00 | 2.17E-02 | ||
| 2.07E00 | 1.82E-02 | ||
| 1.57E00 | 4.55E-02 | ||
| 1.49E00 | 1.1E-02 | ||
| 1.44E00 | 1.04E-02 | ||
| 1.31E00 | 8.16E-03 | ||
| 1.28E00 | 2.86E-02 | ||
| 9.87E-01 | 1.27E-02 | ||
| 9.75E-01 | 1.33E-02 | ||
| 9.46E-01 | 1.22E-02 | ||
Figure 4Effects of deepoxy-DON or 3-epi-DON on activation of MAPK on human intestinal epithelial cells.
(Panel A): Caco-2 cells, differentiated on inserts. (Panel B): Jejunal explants. Samples were treated for 1 h with 10 μM toxins and analyzed by western blot for expression of phosphorylated P38, phosphorylated JNK and GAPDH, used as a protein loading control. Representative immunoblots and normalized expression graph. Results are expressed as mean ± SEM of 3–4 independent experiments, *p < 0.05, **p < 0.01, ***p < 0.001.
Figure 5Interaction between the Ribosome 60S PTC subunit binding site and deepoxy-DON, 3-epi-DON or DON.
Both sides of A site of the yeast ribosome 60S PTC subunit are colored in red and yellow respectively. Hydrogen and oxygen atoms are represented in white and red respectively. (Panel A): detailed views of the co-crystal (4UJX) of DON inside the A-site. (Panel B): detailed view of deepoxy-DON modeling inside the A-site. (Panel C): detailed views of 3-epi-DON modeling inside the A-site. The magnesium atom inside the A-site pocket has been pointed out in green.